WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Bio-K+ International Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
MedTech
TheraVet SA | September 19, 2022
TheraVet a pioneering company in the management of osteoarticular diseases in pets, announced today its participation in the annual congress of the European Society of Veterinary Orthopaedics and Traumatology which will be held from 21 to 24 September at the Acropolis in Nice, France. With nearly 1000 participants, this event is the largest specialised congress in veterinary orthopaedics and traumatology in Europe, bringing together high-quality international speakers and therefor...
Cell and Gene Therapy, Medical
Asher Bio | December 13, 2022
Asher Biotherapeutics, Inc. a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced new preclinical data demonstrating proof-of-concept for cis-targeted cytokines as a novel strategy for enhancing chimeric antigen receptor T cell engraftment, expansion, and functionality culminating in the delivery of improved anti-tumor activity. This data will be presented in a poster at the 64th American Society of Hematology Annual Me...
KYAN Therapeutics | September 24, 2020
KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...
VHL Alliance | April 22, 2020
New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...
Video
Research, Medical
Whitepaper
Cell and Gene Therapy
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE